Diagnostic and therapeutic value of progastrin‐releasing peptide on small‐cell lung cancer: A Single‐Center Experience in China

• Published in: Journal of cellular and molecular medicine Vol. 22; no. 9; pp. 4328 - 4334
• Main Authors: Wu, Xiao‐Yuan, Hu, Yang‐Bo, Li, Hui‐Juan, Wan, Bing, Zhang, Chen‐Xi, Zhang, Bin, Hu, Huan, Zhang, Qun, Lv, Tang‐Feng, Zhan, Ping, Song, Yong
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.09.2018; John Wiley and Sons Inc
• Subjects: Adult; Aged; Antineoplastic Agents - therapeutic use; Area Under Curve; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Carcinoma, Non-Small-Cell Lung - blood; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; China; diagnosis; Diagnosis, Differential; Efficiency; Female; Follow-Up Studies; Humans; Lesions; Lung cancer; Lung diseases; Lung Neoplasms - blood; Lung Neoplasms - diagnosis; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Middle Aged; Neoplasms - blood; Neoplasms - diagnosis; Neoplasms - pathology; neuron‐specific enolase; Non-small cell lung carcinoma; Original; Patients; Peptide Fragments - blood; Peptide Fragments - genetics; Phosphopyruvate Hydratase - blood; Phosphopyruvate Hydratase - genetics; progastrin‐releasing peptide; Recombinant Proteins - blood; Recombinant Proteins - genetics; Retrospective Studies; Sensitivity and Specificity; Small cell lung carcinoma; Small Cell Lung Carcinoma - blood; Small Cell Lung Carcinoma - diagnosis; Small Cell Lung Carcinoma - drug therapy; Small Cell Lung Carcinoma - pathology; small‐cell lung cancer; therapeutic monitoring; China; diagnosis; neuron-specific enolase; small-cell lung cancer; progastrin-releasing peptide; therapeutic monitoring
• ISSN: 1582-1838; 1582-4934
• DOI: 10.1111/jcmm.13722

We aimed to compare the diagnostic efficiency of proGRP and NSE on SCLC and to investigate whether the change of proGRP level would predict therapeutic response. Patients who were firstly diagnosed pathologically in Nanjing Chest Hospital and measured proGRP level consecutively were enrolled in the study. ProGRP level was detected using Elecsys ProGRP Assay. Totally 75 SCLC, 234 NSCLC and 264 benign lung diseases (BLD) were enrolled. Both proGRP and NSE levels in SCLC were significantly higher than those in NSCLC and BLD, and proGRP in extensive stage SCLC was higher than which in limited stage (P ≤ .001). The diagnostic efficiency of proGRP on SCLC was higher than that of NSE, but when the two biomarkers were bind together, the diagnostic efficiency was the best. When SCLC was differentiated from NSCLC and BLD, the cut‐off values were 114.35 pg/mL and 162.55 pg/mL respectively. For treatment responsive patients, proGRP level decreased markedly after the first cycle of therapy and kept a continued momentum of decline during treatment. But for unresponsive patients, no obvious decline was observed. ProGRP had higher diagnostic efficiency on SCLC when compared to NSE, and it could better predict therapeutic response of pulmonary target lesions on chemotherapy.